Employing Broadly Neutralizing Antibodies as a Human Immunodeficiency Virus Prophylactic & Therapeutic Application

Chengchao Ding1†, Darshit Patel2†, Yunjing Ma2, Jamie F. S. Mann2, Jianjun Wu3 and Yong Gao1,2*

1 The First Affiliated Hospital of USTC, Division of Life Science and Medicine, University of Science and Technology of China, Hefei, China, 2 Department of Microbiology and Immunology, University of Western Ontario, London, ON, Canada, 3 Department of AIDS Research, Anhui Provincial Center for Disease Control and Prevention, Hefei, China

Despite the discovery that the human immunodeficiency virus 1 (HIV-1) is the pathogen of acquired immunodeficiency syndrome (AIDS) in 1983, there is still no effective anti-HIV-1 vaccine. The major obstacle to the development of HIV-1 vaccine is the extreme diversity of viral genome sequences. Nonetheless, a number of broadly neutralizing antibodies (bNAbs) against HIV-1 have been made and identified in this area. Novel strategies based on using these bNAbs as an efficacious preventive and/or therapeutic intervention have been applied in clinical. In this review, we summarize the recent development of bNAbs and its application in HIV-1 acquisition prevention as well as discuss the innovative approaches being used to try to convey protection within individuals at risk and being treated for HIV-1 infection.

Keywords: HIV-1, AIDS, bNAb, prevention, therapy

INTRODUCTION

The causative agent of acquired immunodeficiency syndrome (AIDS) is human immunodeficiency virus 1 (HIV-1), a lentivirus from the Retroviridae family (1). HIV-1 predominantly infects CD4+ T cells which play a central role in the adaptive immune system by activating and modulating the activity of other immune cells (2). Individuals with AIDS experience a steady depletion in CD4+ T cells, rendering them severely immunocompromised (3) and susceptible to opportunistic infections (4). Since the first published report of AIDS, in June 1981 (5), 35 million people have died from AIDS-related illnesses. Despite educational and preventative measures, approximately 38 million people are currently living with HIV-1 and 1.7 million new infections are reported in 2019 (http://www.unaids.org/en). The disease has a disproportionate prevalence with a major dominance in Africa, where it has dramatically decreased life expectancy and economic growth (3, 6, 7). Nevertheless, with thorough scientific investigation, several breakthroughs have been made to alleviate the lethality and devastating impact this disease has had on communities. The development of combination anti-retroviral therapy (cART) was a crucial event in decreasing HIV-1-associated morbidity and mortality (8–10). The efficacy of ART is characterized by its ability to inhibit various aspects of the HIV-1 replication cycle and thereby sustain viral loads below the limits of detection.
Consequently, effective viral suppression by ART will improve the immune function, reduce AIDS-related complications, and improve the overall quality of life (10–12). More importantly, HIV-1 acquisition has transformed from a highly lethal infection to a life-long, treatment-manageable affliction. Despite these positive implications, ART can’t cure the disease due to the existing of HIV-1 latent reservoir. Moreover, it may raise significant concerns on the sustainability and affordability of ART and create a potential for global economic issues to enforce HIV-1 patients to a lifelong dependency on ART (13). Neutralizing antibodies (NAb) therapy or effective induction of its production as one of the most promising alternative method have received extensive attention. In this review, we will discuss the targets of antibody responses on HIV-1 envelope (Env), the generation of such antibodies, and the progress and viability of current HIV-1 prophylactic and therapeutic methodologies, with a major focus on leveraging bNAb for HIV-1 prophylactic and therapeutic applications.

HIV-1 ENVELOPE

HIV-1 Envelope, Diversity and the Obstacles for Anti-HIV-1 Vaccine Development

It is widely believed that the holy grail of HIV-1 prophylactic vaccine development is an Env-based immunogen that elicits broad immune response against a wide array of HIV-1 strains. However, the HIV-1 Env glycoprotein has several special characteristics that render the virus evading the attack from host immune response. The HIV-1 genome consists of two copies of single stranded RNA surrounded by a capsid and by a viral membrane. Situated on the outer membrane are Env glycoproteins that are incorporated into the virions as they bud from the host cell. The Env glycoprotein of HIV-1 is synthesized in the rough endoplasmic reticulum and processed into gp120 and gp41 via cleavage by host protease furin (14, 15). Surface gp120 and the transmembrane gp41, associated noncovalently, are determinants of viral tropism and are involved in the promotion of viral and host cellular membrane fusion by recognizing and interacting with particular receptors (16). Specifically, Env gp120 serves as the receptor-binding component and engages CD4 and a coreceptor (CCR5 or CXCR4), while gp41 serves as a means for viral core entry into the host cell. The successful binding and entry of HIV-1 involves several conformational changes that expose conserved regions of the virus and typically occurs in a two-step process outlined in detail by Wilen et al. (17). Briefly, CD4 binding to the constitutively accessible CD4 binding site (CD4bs) on gp120 induces a conformational change, which triggers both high affinity CD4 binding and structural rearrangement of the Env trimer to reveal the chemokine-binding site. The exposure of chemokine-binding site promotes further engagement by gp120 and induces another conformational rearrangement of the Env trimer, triggering gp41 activation. The consequent refolding of gp41, as a result of its activation, induces viral and target cell membrane fusion and subsequent deposition of the viral core within the target cell (17). Env proteins are amongst the most immunogenic components of HIV-1 particles as they are accessible targets being expressed on the viral membrane (18, 19).

Although the ability of HIV-1 to rapidly mutate its genome enhances antigenic variation of surface glycoproteins, the domains that bind to CD4 and co-receptor are relatively conserved. gp120 possesses five conserved regions (C1-C5) that are interspersed between five regions of considerable sequence variability, often called hypervariable loops (V1-V5) (20). The variable regions occlude the constant regions, thus antibodies are primarily raised against variable regions rather than constant regions (20).

The extreme genetic diversity of the virus results from its highly error-prone reverse transcriptase, a high tendency for recombination driven by the constant evolutionary pressure of avoiding detection and destruction by the immune system, and an extremely rapid turnover in vivo (21, 22). Currently, there are four distinct groups of HIV-1: M, N, O and P. Group M is further subdivided into nine distinct subtypes (A-D, F-H, J, and K) and numerous additional circulating recombinant forms (CRFs) (21, 23). Some of these CRFs have recombined with other subtypes or other CRFs to form “second generation” recombinants (9). Genetic inter-clade diversity ranges from 20–30%, diversity within clades reaches as high as 12%, and circulating viruses can differ within the highly variable Env protein by up to 38% (22, 24). As a consequence, this vast diversity of the virus makes it very difficult to design an immunogen that can account for all existing variants of HIV-1.

Moreover, HIV-1 utilizes host-derived, non-immunogenic glycans to mask its Env to evade immune recognition (25–27). gp120 contains approximately 25 N-glycosylation sites that form a glycan shield, which serves as another mechanism to overcome immune defenses (20). Nearly 50% of Env’s molecular mass is composed of host derived N-linked sugars, and such carbohydrate moieties prevent immune recognition by occluding highly immunogenic epitopes on gp120 (18, 28). The role of Env glycans in attenuating recognition by immune cells has been demonstrated in several studies where removal of specific glycans in V loops, within C2-C4 region, and gp41 exposed relevant bNAb epitopes (29–31). In one such study, rhesus monkeys infected with Simian Immunodeficiency Virus (SIV) mutants lacking glycosylation in the V1 region of gp120 resulted in the production of higher neutralizing antibody titers than those infected with wild type SIV (32). Specific to the recessed pocket on gp120 containing the CD4bs, removing glycans peripheral to it increases the sensitivity of the virus to neutralization (33–35).

Types of Humoral Response Against Env

It has been reported that bNAb neutralizing heterologous viruses of diverse subtypes could be developed during chronic infection in a small portion of HIV-1 infected individuals (36, 37). The resultant antibodies can be classified into three groups based on their ability to target and neutralize a range of HIV-1 strains (Figure 1) (41). The first group of antibodies
involves a class of antibodies that are unable to neutralize viruses, including those that have Env sequences identical to immunizing antigen. However, it is still likely that such non-neutralizing Ab (nNAb) can perform antiviral function through Fc-mediated activities (41). Antibodies bound to the Env proteins can attach to FcR expressed on innate immune cells and trigger Ab-dependent cellular cytotoxicity (ADCC) and Ab-mediated cellular phagocytosis (ADCP). ADCC is mainly mediated by natural killer (NK) effector cells, whereas monocytes, macrophages or dendritic cells that can internalize Ab-bound virus or Ab-coated cells are responsible for ADCP (42). These two Fc-mediated processes are dependent on IgG subclass and Fc glycosylation, with some mutations of the Fc region, such as the removal of the Fc glycan fucose residues, increasing the effectivity of ADCC (41).

The second group of antibody response encompasses antibodies that neutralize virus but in a highly strain-specific, autologous manner. Often, these antibodies exert selective pressures that drive viral resistance to the humoral response. Consequently, they promote survival of escape variants that have been generated via insertion/deletion mutations in gp120 variable regions through amino acid substitutions and changing surface glycosylation sites (18, 19, 43, 44).

The third group of antibodies is associated with a response able to neutralize a wide array of HIV-1 strains and is therefore termed bNAb. In vitro, bNAb have been confirmed to neutralize the majority of HIV-1 strains with a half maximal inhibitory concentration (IC50) of less than 1 μg/ml (41, 45). The known spectrum of bNAb targets encompass the CD4bs, glycan-dependent epitopes V1/V2 and base of V3/C3, linear epitopes in the membrane proximal external region (MPER) of gp41, gp120 interface, gp120 silent face, and fusion peptide. (Figure 1).
ANTI-HIV-1 ANTIBODIES

First Generation bNAbs

During chronic HIV-1 infection, approximately up to 50% of infected individuals produce high levels of neutralizing antibodies (NAbs) against Env (36, 58, 59). Among them, approximately 1% are “elite neutralizers” and produce bNAbs, typically after 2-4 years (60). The first-generation anti-HIV-1 bNAbs were discovered when researchers found antibodies capable of neutralizing different HIV-1 subtypes in the early 1990s. These bNAbs were isolated by using phage display or human hybridoma electrofusion. The first generation bNAbs include b12 (CD4bs), 2G12 (viral glycan), 2F5 and 4E10 (gp41 MPER) (Table 1) (71). 2G12 bNAb recognizes α1→2 mannose residues proximal to V3 and V4 loops on gp120 (116). The epitope recognized by 2G12 is conformationally sensitive, strongly depending on asparagine glycosylation in the C2-, C3-, C4-domains, and the V4 loop (20). 2F5 and 4E10 possess a unique ability to bind strongly to the MPER region with one Fab fragment, while having a low affinity for an alternative target on Env with the other Fab fragment (72). This mode of heterogenous binding seems to increase the neutralization efficacy of primary HIV-1 isolates.

Studies carried out with HIV-1 pseudoviruses of different subtypes have demonstrated that first-generation bNAbs exhibit low to moderate breadth and neutralization potencies (20). Therefore, achieving the desired efficacy as a therapeutic requires high concentrations of these bNAbs, with an inherent limitation to the range of HIV-1 isolates that can be neutralized. Additional undesirable characteristics of first generations bNAbs that impede their therapeutic applications have also been outlined. Firstly, 2G12 has a unique structure where each light chain (LC) is bound to the constant region of one heavy chain (HC) and variable region of the other heavy chain, resulting in the cross-association of the HCs, and consequently the Fab-fragments are also unusually closely aligned (20). Moreover, 2F5 and 4E10 are self-reactive and b12 is a phage-derived Fab-fragment Ab generated by random pairing of heavy and light chains that may have never existed in nature (71).

Second Generation bNAbs

The discovery of high throughput single-cell B-cell receptor (BCR) amplification and novel soluble Env selection tools, together with the ability to culture memory B cells, has permitted identification and isolation of second generation bNAbs that are more potent and have a broader coverage (38, 50). Within these, antibodies that bind to the CD4bs are among the broadest, reaching coverage of up to 98% against cross clade viruses (73). The classification of CDbs bNAbs is divided into two major types, complementarity-determining region 3 (CDRH3) dominated and VH-gene restricted, based on their ontogeny and mode of recognition. CDRH3 dominated bNAbs make contact with their target site on the Env primarily through their CDRH3 regions and can be subdivided into four classes: CH103, HJ16, VRC13, and VRC16 classes; whereas VH-gene restricted CD4bs bNAbs make contact primarily through their CDRH2 regions and are subdivided into two classes: VRC01-class antibodies and 8ANC131-class antibodies (74). VRC01, VRC02, and VRC03 were isolated in 2010 from an HIV-1-infected individual living with untreated infection for over 15 years (61). These three bNAbs are highly somatically mutated somatic variants. While VRC01 and VRC02 are somatic variants

TABLE 1 | Categories, efficacies, and research development of broadly neutralizing HIV-1 antibodies.

| Target site (see Figure 1) | Antibody designation | Potency* (Median IC50,μg/mL) | Breadth (% of n pseudoviruses, IC50<50μg/mL) | Similar monoclonal antibodies | Year generation | References |
|---------------------------|----------------------|-----------------------------|---------------------------------|--------------------------------|----------------|------------|
| CD4bs                     | VRC01                | 0.25                        | 91                              | VRC02, VRC03, VRC232          |                 | (61)       |
|                           |                      |                             |                                 | HIHI45-46, 3BNC60, 3BNC62, 3BNC117, 12A12, 12A21, 12A30, VRC-PG04, VRC-CH31 |                 |            |
|                           | HJ16                 | 1.16                        | 36                              | ?                             | 2010           | (62)       |
|                           | b12                  | 1.79                        | 40                              | ?                             | 1991           | (63)       |
|                           | CH103                | 4.54                        | 55                              | CH104 to 106                   | 2013           | (64)       |
|                           | N6                   | 0.04                        | 98                              | ?                             | 2016           | (65)       |
| V1/V2 loop                | PG9                  | 0.109                       | 78                              | PG16, CH101                   | 2009           | (50)       |
|                           | PGT145               | 0.3                         | 78                              | PGT141 to 144                  | 2011           | (66)       |
|                           | 2G12                 | 1.45                        | 28-39                           | ?                             | 1994           | (67)       |
| V3 loop                   | PGT121               | 0.07                        | 70                              | PGT122, PGT123                | 2011           | (49)       |
|                           | 10-1074              | 0.006                       | 66                              | ?                             | 2012           | (49)       |
|                           | 2F5                  | 1.44                        | 67                              | m66                           | 1992           | (68)       |
|                           | 4E10                 | 1.303                       | 98                              | ?                             | 1994           | (69)       |
|                           | 10E8                 | 0.222                       | 98                              | 7H6                           | 2012           | (52)       |
| gp120-41                  | 8ANC195              | 0.415                       | 66                              | 8ANC3040, 8ANC3484             | 2014           | (53)       |
| interface                 | 35022                | 0.033                       | 62                              | ?                             | 2014           | (54)       |
| gp120 silent              | VRC-PG05             | 0.8                         | 27                              | VRC-PG04                      | 2018           | (56)       |
| face                      | SF12                 | 0.2                         | 62                              | SF5                           | 2019           | (55)       |
| Fusion peptide            | ACS2022              | 0.142                       | 45                              | PGT151                        | 2017           | (70)       |
|                           | VRC34.01             | 0.3599                      | 49                              | PGT151                        | 2016           | (57)       |

*For neutralization potency, the geometric mean value among neutralized viruses is shown. TZM-bl/pseudovirus neutralization assay was used to evaluate the neutralization potencies and breadths of the antibodies.

?, unknown.
of the same IgG1 clone with identical CDRH3 regions, VRC03 likely originated from a different IgG1 clone although derived from the same heavy chain alleles as VRC01 and VRC02 (61). It has been demonstrated that VRC01 can neutralize 91% of pseudovirions (of 190 Env-pseudotyped viral strains representing all major clades and circulating recombinants) at an IC50 of <50 μg/mL, and neutralize 72% of primary isolates at an IC50 of <1 μg/mL (38, 61). VRC02 exhibited similar properties as VRC01, however VRC03 was much less broad than VRC01 and VRC02, neutralizing 57% of the pseudovirions at an IC50 of <50 μg/mL.

Following the discovery of VRC01, numerous other CD4bs-targeting antibodies were identified, including, NIH45-46, 3BNC117, and 12A12. NIH45-46 is a more potent clonal variant of VRC01 with high sequence and structural similarities to VRC01, yet it has a distinct mode of binding to gp120 (47). An amino acid substitution from glycine (G) to tryptophan (W) at position 54 yielded NIH45-46G54W (47). This mutation increased the interactive surface between NIH45-46G54W and gp120, which resulted in enhanced potency and breadth (47). For many years since its discovery in 2011, 3BNC117 had the greatest potency and breadth of all the CD4bs-targeting second generation bNAbs; the majority of tested viruses were more sensitive to 3BNC117 than VRC01 (74). 3BNC117 has been tested in phase Ia clinical trial to verify its safety and potential in suppressing viral rebound during ART treatment interruption (75). Recently discovered monoclonal CD4bs antibody, N6, is the most potent bNAb described thus far, and has one of the highest neutralization breadths. In a study involving 181 pseudoviruses from various clades, N6 was able to neutralize 96% of viruses at a median IC50 of 0.038 μg/mL. Focusing on clade C pseudoviruses, N6 neutralized 98% of 171 at a median IC50 of 0.066 μg/mL. N6 has a unique mode of Env recognition, including its ability to avoid steric clashes with the highly glycosylated V5 region as well as ability to tolerate loss of antibody contacts with the CD4bs or V5 region (65, 73). These properties enable N6 to overcome major mechanisms of resistance, thus it is able to neutralize many isolates that were resistant to VRC01 and other CD4bs antibodies (73).

Somatic variants PG9 and PG16, discovered in 2009, were among the first bNAbs identified to target the gp120 V1/V2 loops. Characteristic features of antibodies targeting the V1/V2 loops include exceptionally long CDRH3 arms to penetrate through loops. Targeting antibodies were identified, including NIH45-46, 3BNC117, and 12A12. NIH45-46 is a more potent clonal variant of VRC01 with high sequence and structural similarities to VRC01, yet it has a distinct mode of binding to gp120 (47). An amino acid substitution from glycine (G) to tryptophan (W) at position 54 yielded NIH45-46G54W (47). This mutation increased the interactive surface between NIH45-46G54W and gp120, which resulted in enhanced potency and breadth (47). For many years since its discovery in 2011, 3BNC117 had the greatest potency and breadth of all the CD4bs-targeting second generation bNAbs; the majority of tested viruses were more sensitive to 3BNC117 than VRC01 (74). 3BNC117 has been tested in phase Ia clinical trial to verify its safety and potential in suppressing viral rebound during ART treatment interruption (75). Recently discovered monoclonal CD4bs antibody, N6, is the most potent bNAb described thus far, and has one of the highest neutralization breadths. In a study involving 181 pseudoviruses from various clades, N6 was able to neutralize 96% of viruses at a median IC50 of 0.038 μg/mL. Focusing on clade C pseudoviruses, N6 neutralized 98% of 171 at a median IC50 of 0.066 μg/mL. N6 has a unique mode of Env recognition, including its ability to avoid steric clashes with the highly glycosylated V5 region as well as ability to tolerate loss of antibody contacts with the CD4bs or V5 region (65, 73). These properties enable N6 to overcome major mechanisms of resistance, thus it is able to neutralize many isolates that were resistant to VRC01 and other CD4bs antibodies (73).

Somatic variants PG9 and PG16, discovered in 2009, were among the first bNAbs identified to target the gp120 V1/V2 loops. Characteristic features of antibodies targeting the V1/V2 loops include exceptionally long CDRH3 arms to penetrate through the gp120 glycan shield to access the protein surface beneath (20). PG9 and PG16 possess notable neutralization breadth and potency, capable of neutralizing 78% and 73% of pseudoviruses, respectively (50). CAP256 was isolated from an HIV-1 subtype C-infected individual and has a tendency to neutralize subtype A and C viruses (76). CAP256 has a long CDRH3 loop that binds to a quaternary epitope within V1/V2 region, however it is highly specific for residues 159-171 in the V2 loop that make up the FN/ LRD-K-K motif (76). PGDM1400, isolated in 2014, also interacts with the gp120 V1/V2 quaternary epitope and exhibited high breadth (neutralized 83% of viruses in a cross-clade 106-virus panel) and remarkable potency (median IC50 of 0.003 μg/mL) (77).

A number of broad and potent bNAbs that target the V3 loop region have been described, including PGT121, PGT128, PGT135, 10-1074, and AIIMS-P01. The high-mannose glycans on N332 are commonly targeted by these bNAbs, and they also possess long CDRH3 loops to penetrate the gp120 glycan shield (20). PGT121 utilizes a unique mode of action of neutralization by inhibiting CD4 binding to gp120 through allosteric mechanisms (78). It is postulated that allosteric interactions between PGT121 and key structural elements within V3 locks gp120 into a conformation that impedes CD4 binding. It is worth noting that PGT121 and 10-1074, in contrast to the other V3 loop-targeting bNAbs, bind to complex-type rather than high-mannose glycans on gp120 (49). AIIMS-P01 was recently isolated from a clade C chronically infected pediatric elite neutralizer. It is an HIV-1 N332 supersite-dependent bNAb and can neutralize 67% of HIV-1 cross-clade viruses (79).

The fourth major site of vulnerability that bNAbs can target is gp41 MPER. 10E8 is an MPER-specific antibody that demonstrated ability to neutralize 98% of tested pseudovirions at an IC50 of <50 μg/mL (52). 10E8 possesses a 22-amino-acid long CDRH3 loop that makes contacts with highly conserved hydrophobic gp41 residues, along with a narrow band of residues from CDRH1 and CDRH2 (52). Unlike other MPER-targeting antibodies, 10E8 is neither polyreactive nor lipid-binding (52). In recent years, three other bNAbs targeting sites, including gp120-41 interface, gp120 silent face and fusion peptide, were discovered. The bNAbs, relevant targeting sites, neutralization properties and breadths were showed in Figure 1.

Role of Non-Neutralizing Antibodies (nNAbs)

Neutralizing Abs generally bind to epitopes on functional trimeric Env and prevent subsequent virus-cell engagement, ultimately preventing infection. On the other hand, nNAbs commonly bind non-functional conformations and epitopes absent from functional Env spikes. Such conformations include open Env trimers, gp140 monomers, and cell receptor engagement-induced gp41 stumps (Figure 1). In several studies utilizing humanized mice, it has been demonstrated that nNAbs can provide protection through its Fc region (inhibited the mediation of ADCC and ADCP), while also placing selective pressure and evolutionary constraints on the viruses (80, 81). In one such in vivo study, Horwitz et al. demonstrated that although nNAbs are less efficacious than bNAbs, they can provide modest protection against and change the progress of HIV-1 infection. To show this, a replication competent HIV-1 indicator strain (HIVivoHA) was generated with the ability to express HA-tag on the surface of replication competent HIV-1 indicator strain (HIVivoHA) was used to infect cells.

Figure 1
the number of founder variants, however, they do not protect against infection (82, 83). The conflicting results point to the lack of clarity of the sufficiency of Fc associated protection by nNAb against HIV-1 infection. Besides, nNABS segment Fc also mediates antibody-dependent cell-mediated virus inhibition (ADCVI) and antibody-dependent complement–dependent cytotoxicity (ADCC) via binding to the corresponding Fc receptors (FcγRs) on the surface of effector monocytes, macrophages, dendritic cells, or natural killer cells.

In a recent study, Anand et al. showed that two ADCC-mediating antibodies, anti-coreceptor binding site (CoRBS) and anti-cluster A antibodies, preferentially bind to the open conformation of Env glycoprotein (84). The binding of anti-CoRBS Abs resulted in the further open conformation of Env, facilitating anti-cluster A antibodies interact with the protein. They found that it is required that both antibodies bind to the same gp120 for the subsequent interaction with soluble dimeric FcγRIIIa. Furthermore, Fc regions of the two Abs are required to mediate robust ADCC, indicating that they act in a sequential and synergistic fashion.

**GENERATION OF BNABS**

**Possible Mechanisms for Generation of bNABS**

B cell maturation is one of the proposed mechanisms for the humoral system developing bNABS. The B cell repertoire consists of follicular (FO), marginal zone (MZ), plasmablast and plasma cells, as well as memory B cells. FO B cells, which are mature but inactive, are the most common type of B cells (85). They have a distinct phenotype from other B cell populations, recirculate in the blood, and can become either antibody-producing plasma or memory B cells with help from cognate T cells. They are responsible for generating the majority of high-affinity antibodies during an infection. MZ B cells are found mainly in the marginal zone of the spleen and lymph nodes and serve as the first line of defense against blood-borne pathogens (86). They preferentially undergo T cell independent activation, but can go through T cell dependent activation as well (85). Memory B cells are dormant B cells that arise from B cell differentiation following prior antigen recognition and T cell help (87). During chronic presence of HIV-1 specific antigens, these memory B cells go through multiple rounds of affinity maturation which allows for the gradual recognition of viral variants that emerge over time, and leads to the potential production of bNABS (43, 88–90).

Germinal centers (GC) are the conveyors of affinity maturation. GCs consist of antigen-specific B cells that undergo proliferation and multiple rounds of somatic hypermutation (SHM) of the BCR in the dark zone, and subsequent selection in the light zone. Here, a fraction of the selected B cells returns to the dark zone for additional proliferation and rounds of mutations (91). Mutations in the BCR can alter its affinity towards its specific antigen. B cells possessing a high affinity BCR will capture more antigens and consequently express more antigen derived peptide on its MHC-II, and thus receive more help from follicular helper T cells (Th) cells (39, 40). Th cell help involves many molecules including CD40L, IL-21, IL-4, CXCL13, and SLAM. In one mouse study, one of two populations of GC B cells with the same BCR was given additional Th help. The population of GC B cells that received extra Th help showed increased clonal expansion. Collectively, help provided by Th cells contribute to the survival, proliferation, somatic hypermutation, and isotype class switching of GC B cells, all of which combine to select for high affinity B cells clones by Th cells (39). GC Th cells are not only necessary but also limiting in the production of HIV-1 bNABS. In a human cohort, using a combination of Th cell surface markers to track Th cells, the authors demonstrated a correlation between frequency of memory Th cells and anti-HIV-1 bNAb generation (92). Similarly, at the primate level, SIV and Simian-Human Immunodeficiency Virus (SHIV) challenge studies in rhesus macaques have also shown an association between Th cells and generation of NAb breadth. Additionally, rhesus monkeys with the highest frequency of GC Th cells developed the highest SIV Env-specific antibody titers (93). Another study postulates that increasing the magnitude of HIV-1-specific Th response, or the breadth of the Thf repertoire, can facilitate the evolution of anti-HIV-1 bNABS (94).

The key players and complex interplay of genetic factors predisposing to bNAb development are still being investigated, however, predisposition to natural control of HIV-1, evident in elite neutralizers, involves HLA-1 alleles that allow for a robust CD8+ T cell response (95). Inherently, characteristics of the immune system actually restrict the development of bNABS. The relatively long CDRH3 typical of bNABS, are generated at the stage of V(D)J recombination, and therefore restricting the human immunoglobulin repertoire in the variety of specific V (D)J rearrangements encoding germine precursors of HIV-1 bNABS. This in turn explains the rarity of their presence. Conversely, the accumulation of a large number of mutations, generated by somatic hypermutation during multiple cycles of affinity maturations are also difficult to sustain (90).

The involvement of B-cell dysfunction is also a potential topic of study in the development of bNABS. As a collateral from virus replication and mass-immune activation in HIV-1 infection, the B cell compartment undergoes profound dysregulation. Indicators of B cell dysregulation involve the delayed antibody response in acute infection, an increased activated memory B cell and exhausted B cell subpopulations, polyclonal immunoglobulin production through non-specific activation of plasmablasts, and reduced population of long-lived plasma cells (96–101). B cell dysregulation may be attributed to the transport of Nef to B cells via infected macrophages. Introduction of Nef to B cell may alter class-switching and germinal center responses (102). An alternate but equally likely cause of B cell dysregulation may be the early cytokine storm associated with HIV-1 infection and constitutive dysregulation caused by infection and depletion of T cells (103). Despite the effects of B cell dysfunction, it does not prevent the generation of bNABS which requires further investigation. No correlation has been observed between the
extent of dysfunction of circulating B cells during chronic infection and breadth of neutralization (37, 104).

It has been shown that the development of anti-HIV-1 bNAbs is associated with high genetic diversity of HIV-1 Env glycoprotein and its evolution. Mabvakure et al. compared the evolution of Env in eight HIV-1 patients developing bNAbs with six donors with similar viral loads but without bNAb developed over three years of infection (105). They found that overall evolutionary rates ranged from $9.92 \times 10^{-3}$ to $4.1 \times 10^{-2}$ substitutions/site/year and viral diversity from 1.1% to 6.5% across Env, and there was no significant difference between bNAb donors and non-bNAb donors. Interestingly, in the targeted epitopes, patients with bNAb had more positively selected residues than those without bNAbs, and the selection pressure increased at these residues along with the onset of breadth. These data indicate that the induction of HIV-1 bNAbs is most likely resulting from the highly directed evolution for virus.

Simonich et al. described the bNAb evolution in an infant for the first time. In the BF520.1 V3-glycan directed lineage of this infant, there was evolution of heterologous cross-clade neutralizing activity within 6 months of infection. Interestingly, to achieve the full breadth of the mature antibody, they found that only 2% SHM was needed, and that the features of pathway for this infant antibody development were distinct from adult antibodies, which may be amenable to better vaccine responses (106).

**Eliciting a bNAb Response Using Immunogens**

In an attempt to effectively elicit a broad humoral immune response, various vaccine strategies have been explored, including designing of consensus or ancestral proteins (107–110), modifying Env variable regions or glycosylation sites (107, 110), and replicating Env-CD4 fusion transient intermediates (110, 111). To overcome HIV-1 diversity in particular, a frequently used method is the sequential immunization strategy. This strategy revolves around the idea that by sequentially exposing the host to a collection of Env variants representing the viral quasispecies members isolated from an individual that developed bNAbs, the host is able to undergo a virtually different humoral response. Diversification of the Env gene would drive antibody maturation by presenting new epitopes in diversified variants and focus the humoral response on more conserved epitopes (110) (Figure 2).

Alternatively, a novel vaccine priming strategy that emphasizes germline as the target and initiates the affinity and maturation of specific germline precursor B cells has been of great interest. This strategy allows for immunofocusing by preferentially activating bNAb-precursor B cells, subsequently allowing for productive bNAb-like somatic mutations, and ultimately resulting in the production of memory B cells that can be boosted with Env immunogens to select for additional productive mutations (8, 112, 113). In some cases, inferred germline (iGL) precursors of bNAbs, particularly ones involving the V1/V2 loops at the apex of the trimer, have high affinity for native Env from particular HIV-1 isolates (114, 115), simplifying the design of priming immunogens to be derived from Env of these isolates (77, 116). For other iGL bNAb precursors, no such wild-type Env has been found to bind with high affinity (113, 117), thus requiring the design of modified Env as the priming immunogen. An example of such an immunogen is the eOD-GT8 molecule which has been designed and selected to bind with varying affinity to various iGL versions of VRC01-like bNAbs (118). The efficacy of designed priming immunogens has been evaluated in immunization experiments in mouse models that have been engineered to have the precursor form of VRC01 IgH or IgL genes integrated into the corresponding mouse Ig loci. Using these “knock-in” mice, a single eOD-GT8 immunization was demonstrated to stimulate the production of a VRC01-class memory response in at least 29% of the immunized mice despite the presence of a low frequency of VRC01-class precursor per mouse (118). It is expected that after the priming of germline precursor, a potent induction of bNAbs will require sequential boosts, driving a succession of germinal-center reactions to select sufficient mutations.

In a recent study, by using neutralization data from four large virus panels, Bricault et al. mapped viral signatures comprehensively with bNAb sensitivity, including amino acids, hypervariable region characteristics, and clade effects across four different classes of bNAbs (119). They then employed the bNAb signatures (defined for the V2 epitope region of HIV-1 Env) to design a signature-based epitope targeted (SET) vaccine. A trivalent vaccine (V2-SET) was created by introducing V2 bNAb signature-guided mutations into Env 459C, and was used to immunize guinea pigs. The results showed that V2-SET vaccines elicited broader NAb responses when compared with Env 459C alone, indicating that bNAb signatures could be utilized to inform HIV-1 Env immunogens design to elicit antibody responses with greater neutralization breadth.

**APPLICATION OF bNAbs: AN ARSENAL OF PROTECTIVE POTENTIAL**

**Passive Immunization**

As an alternative to vaccine development, passive immunization is being explored as a potential therapeutic for treatment and prevention of HIV-1 infection. In early preclinical animal studies involving passive transfusion of HIV-1 neutralizing sera and first generation bNAbs, relatively effective protection was conferred against certain HIV-1 strains (120). However, due to the poor breadth and potency of first generation bNAbs, and primarily the cost of manufacture and feasibility, passive immunization was not pursued further (121). Nevertheless, with the discovery of more potent and broad second generation bNAbs, such as VRC01 and its clonal variants, research into passive immunization has resurfaced and has demonstrated prevention and treatment potential against lentiviral infection in macaques, humanized mice, and humans (122–132). In one such study, intravenous transfusion of PGT121 mediated sterilizing immunity against SHIV in monkeys at lower concentrations
than those observed in previous studies (132). Similarly, administered in monkeys, VRC01 was providing complete protection against high-dose SHIV vaginal and rectal challenge (133). In contrast to a high-dose challenge model, humans are typically exposed to small but multiple doses of HIV-1 via a mucosal route. In a repeated low-dose SHIV intrarectal challenge model, a single administration of bNAb (VRC01, 3BNC117, 10-1074, or VRC01-LS) to macaques was protective against infection for several months. The duration of protection was correlated with the antibody potency and half-life (125). Two V2-specific antibodies, PGDM1400 and CAP256-VRC26.25, have demonstrated high potency and neutralization breadth against HIV-1. Not much exploration has been pursued into V2-specific bNAbs, however PGDM1400 has been shown to be fully protective at 0.4mg/kg dose against SHIV challenge in a macaque model. Similarly, CAP256-VRC26.25 conferred complete immunity at a smaller dosage of 0.08 mg/kg, and thus showing the potential for V2-specific bNAbs as potential passive immunization therapeutic agents (134).

Apart from monkeys, two human clinical trials have also determined that VRC01 passive transfusion is a safe and effective endeavor (135, 136). Passive immunization using VRC01 is now being tested on a larger scale by HIV Vaccine Trials Network (HVTN) and HIV Prevention Trials Network (Antibody Mediated Prevention) and involves 2700 high-risk homosexual men in the Americas (NCT02716675) and 1,900 heterosexual women in Africa (NCT02568215). Participants are intravenously administered with either 10 mg/kg or 30 mg/kg of VRC01 once every week for 8 weeks. A protective titers for passive immunization will be determined by comparing number of
immunization involves high doses of antibodies over a long period of time. First, passive immunization is limited by the absence of a cost-effective and high yield method. The capacity to mediate viral and antigen suppression, with reduced susceptibility for viral evasion, as well as their sensitivity to viral resistance, and its capacity to mediate viral and antigen trafficking, processing, and presentation. Regimens can also depend on the patient's viral load, variants present at the time of therapeutic administration, as well as their sensitivity to specific bNAbs. Collectively, these factors will provide a more personalized regimen that will ensure viral load suppression, with reduced susceptibility for viral evasion, as long as adherence is maintained.

Although passive immunization shows promise, many factors contribute to raise feasibility concerns for its application as a large-scale human prophylactic and therapeutic. First, passive immunization involves high doses of antibodies over a long period of time. Consequently, it requires relatively large amounts of expensive reagents, inflating the cost to treat one patient. Additionally, monoclonal antibodies are difficult to produce in large amounts. Therefore, passive immunization is currently limited by the absence of a cost-effective and high yield method. The capacity to mediate viral and antigen suppression, with reduced susceptibility for viral evasion, as well as their sensitivity to viral resistance, and its capacity to mediate viral and antigen trafficking, processing, and presentation. Regimens can also depend on the patient’s viral load, variants present at the time of therapeutic administration, as well as their sensitivity to specific bNAbs. Collectively, these factors will provide a more personalized regimen that will ensure viral load suppression, with reduced susceptibility for viral evasion, as long as adherence is maintained.

Further studies are required to determine optimal treatment regimens for passive immunization. These investigations can differ based on pharmacodynamics and pharmacokinetics in serum, as well as the bNAb HIV-1-specific pharmacodynamic properties, such as neutralization efficacy, susceptibility to viral resistance, and its capacity to mediate viral and antigen trafficking, processing, and presentation. Regimens can also depend on the patient’s viral load, variants present at the time of therapeutic administration, as well as their sensitivity to specific bNAbs. Collectively, these factors will provide a more personalized regimen that will ensure viral load suppression, with reduced susceptibility for viral evasion, as long as adherence is maintained.

Although passive immunization shows promise, many factors contribute to raise feasibility concerns for its application as a large-scale human prophylactic and therapeutic. First, passive immunization involves high doses of antibodies over a long period of time. Consequently, it requires relatively large amounts of expensive reagents, inflating the cost to treat one patient. Additionally, monoclonal antibodies are difficult to produce in large amounts. Therefore, passive immunization is currently limited by the absence of a cost-effective and high yield method. The capacity to mediate viral and antigen suppression, with reduced susceptibility for viral evasion, as well as their sensitivity to viral resistance, and its capacity to mediate viral and antigen trafficking, processing, and presentation. Regimens can also depend on the patient’s viral load, variants present at the time of therapeutic administration, as well as their sensitivity to specific bNAbs. Collectively, these factors will provide a more personalized regimen that will ensure viral load suppression, with reduced susceptibility for viral evasion, as long as adherence is maintained.

| Antibody | Sponsor | Phase | Estimated end date | Number of participants |
|----------|---------|-------|--------------------|-----------------------|
| NCT041301758 VRC01 | HIV Vaccine Trials Network | Phase II | Jun 2022 | 30 |
| NCT04171074 LS + 3BNC117-LS | Imperial College London | Phase II | Mar 2025 | 72 |
| NCT04400049 UB-241 | UCB Greater China (Shanghai) Co., Ltd | Phase II | Jun 2024 | 39 |
| NCT03743376 UB-241 | United BioPharma | Phase II | Dec 2021 | 31 |
| NCT03147859 vedolizumab | Ottawa Hospital Research Institute | Phase II | Dec 2021 | 24 |
| NCT03721510 PGT121 + VRC07-523LS +/- PGDM1400 | International AIDS Vaccine Initiative | Phase I/II | Oct 2022 | 18 |
| NCT03208231 VRC01 | NAID | Phase II | Feb 2021 | 68 |
| NCT03707977 VRC01LS + 10-1074 | NAID | Phase II | Oct 2021 | 40 |
| NCT03554408 10-1074-LS + 3BNC117-LS | Rockefeller University | Phase I | Jun 2021 | 75 |
| NCT03571204 3BNC117 + 10-1074 | NAID | Phase I | Jun 2021 | 27 |
| NCT03526848 3BNC117 + 10-1074 | Rockefeller University | Phase I | Apr 2022 | 26 |
| NCT04250656 3BNC117-LS + 10-1074-LS | Rockefeller University | Phase I | Feb 2022 | 10 |
| NCT03374202 AAV8-VRC07 | NAID | Phase I | Mar 2027 | 25 |
| NCT03705169 SARI41236 | NAID | Phase I | Mar 2021 | 84 |
| NCT02571402 VRC01 | NAID | Phase I | Mar 2021 | 24 |

N/A, not applicable.
were subsequently challenged with 10ng of NL4-3 HIV-1 strain intravenously. A VRC01 titer of 8.3μg/ml was able to be achieved and provided complete protection against the HIV-1 challenge, thus demonstrating a proof of concept of VIP (142).

However, the intravenous HIV-1 injection model is not entirely representative to human infection, which establishes through the mucosal route. Therefore, to model HIV-1 human infection, a bone marrow-liver-thymic (BLT) chimeric mouse model was intravaginally challenged with a low dose of HIV-1 JR-CSF strain. BLT mice that were given VIP to express VRC01 were highly resistant to this challenge, elucidating the successful VIP-mediated delivery of bNAb and its efficacy of protection against HIV-1 (143). Efficacy evaluation in the nonhuman primate (NHP) model has also been carried out by SIV challenge of macaque monkeys, in which VIP-mediated bNAb expression was detected for over 6 years, providing protection against infection (144). A recent study with the NHP model demonstrated that, after receiving the AAV-encoded multiple bNAbs (38NC117, 10-1074, and 10E8), two antibodies (38NC117 and 10-1074) maintained high level (50-150 μg/mL) in one out of four SHIV-AD8 infected monkeys over two years, and resulted in undetectable plasma viremia over three years (145).

Encouraging results in animal models has rallied substantial interest to push VIP gene transfer therapy to clinical trials. Priddy et al. reported the first-in-human phase I trial (NCT01937455) with rAAV1-PG9DP (encoding PG9) in 21 volunteers performed in the UK (146). There were only mild or moderate reactions without intervention in the participants. PG9 was detected by RT-PCR in muscle biopsy samples in four volunteers and showed HIV-1 neutralization activity in the serum samples. However, ELISA detected no PG9 in serum. On the other hand, ten volunteers in the higher dose groups were detected PG9 anti-drug antibody (ADA), anti-AAV1 antibodies and AAV1-specific T-cell responses. As previously mentioned, anti-HIV-1 bNAbs undergo high levels of somatic hypermutation. Such highly mutated regions serve as potential targets for anti-idiotypic responses, which in turn would diminish their protective activity and lead to the eventual loss of transgene expression (144). Additionally, some bNAbs have a polyreactive characteristic, which allows them to bind to human antigens with high affinity as well (147, 148). For example, VRC01, VRC02, CH106, and CH103 can bind to human ubiquitin ligase E3A with high affinity, with avidity correlating to neutralization breadth of the antibody (149). The combination of auto-reactive bNAbs with the long-term antibody expression achieved by gene therapy creates a potential for autoimmunity. Therefore, before application of VIP gene transfer therapy into clinical use, challenges associated with gene transfer therapy must be addressed, i.e. how to achieve a protective bNAb level in transmission sites while minimizing the side effects caused by long-term bNAb expression.

Additionally, viral rebound occurs rapidly upon bNAbs’ decay (139), which presents opportunities for viral evolution. For passive immunization applications, improving the half-life may reduce adherence complications, in turn reducing the possibility for viral evolution, and preventing both viremia and viral resistance. Previously, bNAbs have been shown to decay more rapidly in HIV-1-infected individuals compared to the uninfected, which may be attributed to the formation of antibody-virus complexes that are readily recognized and cleared (139). Taking this into account, serum half-life needs to be improved to maintain concentrations required for protective potential and constrain viral evolution in those who are already HIV-1-infected. One such methodology, involving Fc engineering, introduces two mutations encoding amino acid substitutions (M428L and N434S, collectively known as LS) into genes encoding Fc domains of VRC01. Compared to its wild-type counterpart, VRC01-LS (now being explored in Phase I clinical trials: NCT02797171, NCT02599896) demonstrated a 3-fold increase in its half-life, accompanied by an increase in its ability to translocate to mucosal tissues and protection against high-dose rectal challenge in non-human primates (150–152). Similarly, 38NC117-LC and 10-1074-LC have also demonstrated to have a 2.0 and 3.8-fold increase in half life, respectively (125).

**HIV-1 Resistance to bNAbs**

HIV-1 resistance to bNAb neutralization has been ever increasing over the course of the epidemic. In a previous study, HIV-1 variants isolated from recently infected individuals and from those infected early in the epidemic were tested for their sensitivity to first and second generation bNAbs. It was demonstrated that HIV-1 variants from recently infected individuals showed a decrease in sensitivity to neutralization from single to second generation bNAbs. It was demonstrated that HIV-1 variants from recently infected individuals showed a decrease in sensitivity to neutralization from b12, but not to 2G12, 2F5, or 4E10. Of the 21, at least one variant from recently infected patients also showed decreased neutralization sensitivity to PG16, PG9, and VRC01, one of the most potent bNAbs thus far described (153). It has been previously established that neutralization escape from single antibody administration can occur rapidly (132). Nonetheless, a cocktail of 3-4 bNAbs can be used to reduce chances of resistance development while being capable of neutralizing 100% of viruses. Although bNAbs can prevent and control an HIV-1 infection, their breadth is invariably too limited for use as monotherapy. To address this problem, bispecific and trispecific antibodies have been developed. A recent study reported that a new class of bispecific antibodies targeting the V2-glycan (apex) and V3-glycan regions of the HIV-1 Env showed more potent neutralization than their parental bNAbs (154). Despite its positive implications, the use of more than one bNAb in therapeutic and prophylactic strategies increases the cost of the product, raising feasibility concerns.

**Anti-Drug Antibodies**

Due to its longer half-life and its ability to efficiently mediate antibody effector functions, the IgG1 subtype is usually selected for AAV delivery of bNAbs. However, it has been discovered that IgG1-Fc is responsible for the generation of anti-drug antibodies (ADAs) which results in loss of antibody expression. To circumvent this issue, Gardner et al. (155) utilized a rhesus IgG2-Fc domain to generate...
an antibody-like molecule eCD4-Ig to express four anti-HIV-1 bNAbs: NIH45-46, 3BNC117, PGT121 and 10-1074. To investigate the ADA and efficacy of these antibodies with either IgG1-Fc or IgG2-Fc domain, they compared AAV1 expression of these antibodies in macaques, and found that the macaques expressing IgG2-isotyped bNAbs were protected from two SHIV-AD8 challenges, but not the macaques expressing IgG1, and observed significantly lower ADA in the former macaques. These data suggest that, when using AAV1 as an expression vector, IgG2-isotyped bNAbs are less immunogenic than their IgG1 counterparts.

Autoimmune Diseases
As previously mentioned, many bNAbs possess autoreactive potential, which has been demonstrated using autoimmune diagnosing assays and testing on arrays of human proteins. In studies involving the tracking of maturation from initial B cell arrangement to breadth development, a correlation was observed between autoreactivity and neutralization breadth. In addition, CH98, a CD4bs targeting bNAb, was isolated from a person living with an HIV-1 infection and systemic lupus erythematosus (SLE). When testing the autoreactivity of CH98, it was found to be capable of binding dsDNA, suggesting that some bNAbs derive from an autoreactive pool of B cells (156). Autoreactivity may pose a problem in gene transfer therapy, where an individual is endowed the ability to endogenously and constitutively produce these bNAbs. A strategy for controlling the endogenous bNAb expression may alleviate some degree of autoimmunity concerns.

Cost-Effectiveness of bNAbs for Protection
The combination of the short half-life (thus requiring repeated administrations of bNAbs in passive immunization) and cost of the clinical-grade reagents required to manufacture bNAbs raise feasibility concerns and impede its applications on a population-wide scale. Targeting bNAbs to anatomical sites of exposure may reduce the number and volume of doses required to provide protection against HIV-1 infection, consequently reducing the cost. Up to now, it remains uncertain whether either infection or vaccination with HIV-1 Env can generate protective mucosal or systemic IgA responses. However, it is crucial to induce long-lived effective mucosal antibody responses for providing protection in mucosal layer. In recent years, important progress has been made in unveiling events that occur during the exposure of HIV-1 to the mucosal surface, one of the predominant infection routes. It is unclear how the initial infection is established in the mucosal layer or mucosally. However, it has been demonstrated that HIV-1 can infect the vaginal, ectocervical, endocervical, and endometrial mucosa. The vagina and ectocervix are covered by an intact multilayered squamous epithelium, providing an intrinsic mechanical protection, while the endometrium and endocervix are covered by a single layer of columnar epithelium. Regardless, HIV-1 can penetrate corresponding cells and cause infection in all four regions mentioned above. Therefore, in addition to potentially reducing the cost of bNAb-involved treatment, targeting bNAbs to the mucosa will increase protection by serving as an alternative line of defense to mechanical barriers (157, 158).

Antibody engineering strategies have been explored to improve and establish bNAb use for mucosal immunity. One strategy involves engineering the Fc region such that it enhances binding to FcRn (neonatal FcR that is involved in IgG transepithelial transport) and plgR (polymeric immunoglobulin receptor that is involved in IgA transepithelial transport). Anti-HIV-1 bNAb variants modified to improve binding ability have been demonstrated to have an extended half-life, enhanced localization and persistence at mucosal surfaces, and superior protection from intrarectal SHIV challenge in macaques (151). Designing IgA and chimeric IgGA variant bNAbs may also increase localization and protection in mucosa. Engineering gene transfer therapy to produce a localized response in mucosal tissue may also be beneficial. Additionally, combination therapy of cART and bNAbs may be a superior substitution to maintain viral suppression in HIV-1-infected humans.

Potential Suboptimal Efficacy in Virus Cell-to-Cell Transmission
Studies have reported that HIV-1 infects target cells via two mechanisms: cell-free virus spread or cell-to-cell transmission (159, 160). More importantly, HIV-1 cell-to-cell transmission showed higher transmission efficiency than cell-free virus spread (161). A number of studies have confirmed that bNAbs could efficiently inhibit intravenous and mucosal infection caused by cell-free HIV-1 or SHIV challenge (125, 162, 163). However, previous studies have demonstrated that cell-mediated HIV-1 transmission is less sensitive to antiretroviral drugs and bNAbs than cell-free viral infection (164, 165). The activities of bNAb-mediated inhibition of cell-to-cell transmission are likely associated with the steric-hinerance effect caused by virological synapse (166). Thus, antibodies with smaller size may show more potent neutralization activity in HIV-1 cell-to-cell dissemination. Duncan et al. found that 10E8 Fab fragment presented more efficient neutralization activity than the original 10E8 in HIV-1 cell-to-cell transmission (167). Additionally, some studies indicated that the activity of bNAbs-mediated inhibition in cell-to-cell transmission mainly depended on mode of action and virus strains (168, 169). Overall, further understanding of the mechanisms of HIV-1 cell-to-cell transmission may promote the future application of bNAbs for inhibiting HIV-1 spread.

CONCLUSION
The progress into characterizing the role and applicability of bNAbs in HIV-1 treatment over the years has rapidly accumulated. More focus and investigation into understanding the mechanism of bNAb generation, however, may be beneficial on several fronts, including the development of an effective vaccine that can elicit a potent bNAb response. Passive immunization over the years has also been improved, and its transition into a population-wide therapeutic can potentially be eased with reduced production cost. Additionally, research in cancer immunology has led to the establishment of gene transfer therapy, which has become a
promising approach for HIV-1 treatment. Efficacy of both passive immunization and gene transfer therapy may significantly benefit from the discovery of more potent bNabs. Moreover, bNAbs-induced protection may be less effective in cell-cell transmission, and therefore, increasing our knowledge on mucosal transmission events and HIV-1 spread through infected cells will provide a strong foundation for improvement.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be available by the authors, without undue reservation.

REFERENCES

1. Sierra S, Kupfer B, Kaiser R. Basics of the Virology of HIV-1 and its Replication. J Clin Virol (2005) 34(4):233–44. doi: 10.1016/j.jcv.2005.09.004
2. Luckheeram RV, Zhou R, Verma AD, Xia B. CD4+ T Cells: Differentiation and Functions. Clin Dev Immunol (2012) 2012:925135. doi: 10.1155/2012/925135
3. McMichael AJ, Rowland-Jones SL. Cellular Immune Responses to HIV. Nature (2001) 410(6831):980–7. doi: 10.1038/35073658
4. Kasper LH, Buzoni-Gatel D. Some Opportunistic Parasitic Infections in AIDS: Candidiasis, Pneumocystosis, Cryptosporidiosis, Toxoplasmosis. Parasitol Today (1998) 14(4):150–6. doi: 10.1016/S0169-4789(97)01212-X
5. Centers for Disease C. Pneumocystis Pneumonia. MMWR Morb Mortal Wkly Rep (1981) 30(21):250–2.
6. Piot P, Quinn TC. Response to the AIDS Pandemic—a Global Health Model. N Engl J Med (2013) 368(23):2210–8. doi: 10.1056/NEJMr1201533
7. Quinn TC. HIV Epidemiology and the Effects of Antiviral Therapy on Long-Term Consequences. AIDS (2008) 22 Suppl 3:537–42. doi: 10.1097/01.aids.0000327510.68503.e8
8. Andrabi R, Voss JE, Liang CH, Briney B, McCoy LE, Wu CY, et al. Identification of Common Features in Prototype Broadly Neutralizing Antibodies to HIV Envelope V2 Apex to Facilitate Vaccine Design. Immunity (2015) 43(5):959–73. doi: 10.1016/j.immuni.2015.10.014
9. Arken KV, Vanham G, Arts EJ. Is HIV-1 Evolving to a Less Virulent Form in Humans? Nat Rev Microbiol (2007) 5(2):141–51. doi: 10.1038/nrmicro1594
10. Autran B, Carcelen G, Li TS, Blanc C, Mathez D, Tubiana R, et al. Positive Effects of Combined Antiretroviral Therapy on CD4+ T Cell Homeostasis and Function in Advanced HIV Disease. Science (1997) 277(5322):112–6. doi: 10.1126/science.277.5322.112
11. Komanduri KV, Viswanathan MN, Wieder ED, Schmidt DK, Bredt BM, Jacobson MA, et al. Restoration of Cytomegalovirus-Specific CD4+ T-Lymphocyte Responses After Ganciclovir and Highly Active Antiretroviral Therapy in Individuals Infected With HIV-1. Nat Med (1998) 4(8):933–6. doi: 10.1038/nm0989-953
12. Lederman MM, Connick E, Landay A, Kuritzkes DR, Spritzler J, St Clair M, et al. Immunologic Responses Associated With 12 Weeks of Combination Antiretroviral Therapy Consisting of Zidovudine, Lamivudine, and Ritonavir: Results of AIDS Clinical Trials Group Protocol 315. J Infect Dis (1998) 178(1):70–9. doi: 10.1086/515591
13. Broder S, Hoffman SL, Hotze PJ. Cures for the Third World’s Problems: The Application of Genomics to the Diseases Plaguing the Developing World may Have Huge Medical and Economic Benefits for Those Countries and Might Even Prevent Armed Conflict. EMBO Rep (2002) 3(9):806–12. doi: 10.1093/embo-reports/kvf187
14. Hallenberger S, Bosch V, Angliker H, Shaw E, Klenk HD, Garten W. Inhibition of Furin-Mediated Cleavage Activation of HIV-1 Glycoprotein gp160. Nature (1992) 360(6402):358–61. doi: 10.1038/360358a0
15. Wyatt R, Sodroski J. The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens. Science (1998) 280(5371):1884–8. doi: 10.1126/science.280.5371.1884

AUTHOR CONTRIBUTIONS

CD, DP, YM, JW, and YG wrote sections and JM and YG reviewed the article. All authors contributed to the article and approved the submitted version.

FUNDING

This work was funded by awards from Anhui Science and Technology Bureau (201904b11020044), CIHR (HBF143165, PJT 149075) and Fundamental Research Funds for the Central Universities (WK911000167).

16. Chan DC, Kim PS. HIV Entry and its Inhibition. Cell (1998) 93(5):681–4. doi: 10.1016/S0092-8674(00)81430-0
17. Wilen CB, Tilson JC, Doms RW. HIV: Cell Binding and Entry. Cold Spring Harbor Perspect Med (2012) 2(8):a006866. doi: 10.1101/cshperspect.a006866
18. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, et al. Antibody Neutralization and Escape by HIV-1. Nature (2003) 422(6929):307–12. doi: 10.1038/nature01470
19. Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid Evolution of the Neutralizing Antibody Response to HIV Type 1 Infection. Proc Natl Acad Sci USA (2003) 100(7):4144–9. doi: 10.1073/pnas.063053100
20. Shcherbakov DN, Bakulina YA, Karpenko LI, Ilyichev AA. Broadly Neutralizing Antibodies Against HIV-1 As a Novel Aspect of the Immune Response. Acta Naturae (2015) 7(4):11–21. doi: 10.23607/20758251-2015-7-4-11-21
21. Korber B, Gaschen B, Yusim K, Khaliappally R, Kemer S, Detours V. Evolutionary and Immunological Implications of Contemporary HIV-1 Variations. Be Med Bull (2001) 58(19):42–8. doi: 10.1093/bmb/58.1.19
22. Walker BD, Burton DR. Toward an AIDS Vaccine. Science (2008) 320(5877):760–4. doi: 10.1126/science.1152622
23. Peeters M, Sharp PM. Genetic Diversity of HIV-1: The Moving Target. AIDS (2000) 14 Suppl 3:S129–140.
24. Lihana RW, Ssemwanga D, Abimiku A, Ndemb N. Update on HIV-1 Diversity in Africa: A Decade in Review. AIDS Rev (2012) 14(2):83–100.
25. Kimura T, Wang XH, Williams C, Zolla-Pazner S, Gorny MK. Human Monoclonal Antibody 2909 Binds to Pseudovirions Expressing Trimers But Not Monomeric HIV-1 Envelope Proteins. Hum Antibodies (2009) 18(1-2):35–40. doi: 10.3233/HAB-2009-0200
26. Kwong PD, Doyle ML, Casper DJ, Cicala C, Leavitt SA, MAeS, et al. HIV-1 Evades Antibody-Mediated Neutralization Through Conformational Masking of Receptor-Binding Sites. Nature (2002) 420(6916):678–82. doi: 10.1038/nature01188
27. Wyatt R, Kwong PD, Desjardins E, Sweet RW, Robinson J, Hendrickson WA, et al. The Antigenic Structure of the HIV Gp120 Envelope Glycoprotein. Nature (1998) 393(6686):705–11. doi: 10.1038/31405
28. Scanlan CN, Offer J, Zitzmann N, Dwek RA. Exploiting the Defensive Sugars of HIV-1 for Drug and Vaccine Design. Nature (2007) 446(7139):1038–45. doi: 10.1038/nature05818
29. Falkowska E, Le KM, Ramos A, Doores KJ, Lee JH, Blattner C, et al. Broadly Neutralizing HIV Antibodies Define a Glycan-Dependent Epitope on the Prefusion Conformation of gp41 on Cleaved Envelope Trimmers. Immunity (2014) 40(5):657–68. doi: 10.1016/j.immuni.2014.04.009
30. McCaffrey RA, Saunders C, Hensel M, Stamatatos L. N-Linked Glycosylation of the V3 Loop and the Immunologically Silent Face of gp120 Protects Human Immunodeficiency Virus Type 1 SF162 From Neutralization by Anti-gp120 and Anti-gp41 Antibodies. J Virol (2004) 78(7):3279–95. doi: 10.1128/JVI.00427-03
31. Wang W, Nie J, Prochnow C, Truong C, Ji Z, Wang S, et al. A Systematic Study of the N-Glycosylation Sites of HIV-1 Envelope Protein on Infectivity.
Ding et al. bNAb for HIV-1 Therapy

50. Walker LM, Huber M, Doores KJ, Falkowkova E, Peijchal R, Julian JP, et al. Broad Neutralization Coverage of HIV by Multiple Highly Potent Antibodies. *Nature* (2011) 477(735):466–70. doi: 10.1038/nature10737

51. Huang I, Ofek G, Laub L, Louder MK, Doria-Rose NA, Longo NS, et al. Broad and Potent Neutralization of HIV-1 by a gp41-Specific Human Antibody. *Nature* (2012) 491(7424):406–12. doi: 10.1038/nature11544

52. Scharf L, Scheid JF, Lee JH, West AP Jr., Chen C, Gao H, et al. Antibody 8anc195 Reveals a Site of Broad Vulnerability on the HIV-1 Envelope Spike. *Cell Rep* (2014) 7(3):785–95. doi: 10.1016/j.celrep.2014.04.001

53. Huang J, Kang BH, Pancera M, Lee JH, Tong T, Feng Y, et al. Broad and Potent HIV-1 Neutralization by a Human Antibody That Binds the gp41-gp120 Interface. *Nature* (2014) 515(7525):138–43. doi: 10.1038/nature13601

54. Schoofs T, Barnes CO, Sub-Toma N, Golijanin J, Schommer P, Gruell H, et al. Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope. *Immunity* (2019) 50(6):1513–++ doi: 10.1016/j.immuni.2019.04.014

55. Zhou T, Zheng A, Buang U, Chuang G-Y, Georgiev IS, Kong R, et al. A Neutralizing Antibody Recognizing Primarily N-Linked Glycan Targets the Silent Face of the HIV Envelope. *Immunity* (2018) 48(3):500–+. doi: 10.1016/j.immuni.2018.02.004

56. Kong R, Xu K, Zhou TQ, Achariya P, Lemmin T, Liu K, et al. Fusion Peptide of HIV-1 as a Site of Vulnerability to Neutralizing Antibody. *Science* (2016) 352(6287):828–33. doi: 10.1126/science.aag0747

57. Pinley JM, Lybarger EA, Crooks ET, Seaman MS, Gray E, Davis KL, et al. Profiling the Specificity of Neutralizing Antibodies in a Large Panel of Plasmas From Patients Chronically Infected With Human Immunodeficiency Virus Type 1 Subtypes B and C. *J Virol* (2008) 82(23):11651–68. doi: 10.1128/JVI.01762-08

58. Gray ES, Moore PL, Choge IA, Decker JM, Biboillet-Ruche F, Li H, et al. Neutralizing Antibody Responses in Acute Human Immunodeficiency Virus Type 1 Subtype C Infection. *J Virol* (2007) 81(12):6187–96. doi: 10.1128/JVI.00239-07

59. Simek MD, Rida W, Priddy FH, Pung P, Carrow E, Lauffer DS, et al. Human Immunodeficiency Virus Type 1 Elite Neutralizers: Individuals With Broad and Potent Neutralizing Activity Identified by Using a High-Throughput Neutralization Assay Together With an Analytical Selection Algorithm. *J Virol* (2009) 83(1):493–504. doi: 10.1128/JVI.00239-07

60. Corti D, Langedijk JPM, Hinz A, Seaman MS, Vanzetta F, Fernandez-Rodriguez BM, et al. Analysis of Memory B Cell Responses and Isolation of Novel Monoclonal Antibodies With Neutralizing Breadth From HIV-1-Infected Individuals. *PloS One* (2010) 5(11):e8805. doi: 10.1371/journal.pone.0008805

61. Saphire EO, Parren P, Barbas CF, Burton DR, Wilson IA. Crystallographic and Computational Methods for Targeting the Infectious HIV-1 Envelope. *J Virol* (2010) 84(3):1180–9. doi: 10.1128/JVI.01669-09

62. Gorman J, McElhaney J, Yang T, Zhou T, Bunguru S, et al. Recombinant Env Proteins That Bind the Quaternary-Specific, V1/V2-Directed PGT Antibodies. *Retrovirology* (2012) 9:84. doi: 10.1186/1742-4690-9-84

63. Kunert R, Rucker F, Katinger H. Molecular Characterization of Five Neutralizing Anti-HIV Type 1 Antibodies: Identification of Nonconventional D Segments in the Human Monoclonal Antibodies
Ding et al. bNAb for HIV-1 Therapy

Kumar S, Panda H, Makhdoomi MA, Mishra N, Safdari HA, Chawla H, et al. (2021) Neutralizing Antibody PGT121 Allosterically Modulates CD4 Binding Antibodies Targeting the Trimer Apex. *J Virol* (2017) 91(16): e00498-17.

Scheid JF, Mouquet H, Ubershade B, Diskin R, Klein F, Oliveira TY, et al. Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding. *Science* (2011) 333(6049):1633–7. doi: 10.1126/science.1207227.

Scheid JF, Horwitz JA, Zoller MJ, Krogsgaard M, Ott RG, Shukair S, et al. Survivors Remorse: Antibody-Mediated Neutralizing Antibodies. *AIDS Res Ther* (2017) 14(1):50. doi: 10.1186/s12981-017-0178-3.

Moir S, Malaspina A, Ogwaro KM, Donoghue ET, Hallahan CW, Ehler LA, et al. B-Lymphocyte Dysfunction in Chronic HIV-1 Infection Does Not Eliminate HIV-1-Infected Cells. *Front Immunol* (2015) 6:10. doi: 10.3389/fimmu.2014.00263-X.

van Gils MJ, van den Kerkhof TLGM, Ozorowski G, Cottrell CA, Sok D, Pauthner M, et al. An HIV-1 Antibody From an Elite Neutralizer Implicates the Fusion Peptide as a Site of Vulnerability. *Nat Microbiol* (2017) 2(2):16199. doi: 10.1038/nmicrobio.2016.199.

Ahmed Y, Tian M, Gao Y. Development of an Anti-HIV Vaccine Eliciting Autologous Evolving Viruses. *An HIV-1 Broadly Neutralizing Antibody From a Clade C-Infected Pediatric Macaques.* *PloS Pathog* (2015) 11(8):e1005042. doi: 10.1371/journal.ppat.1005042.

Santra S, Tomaras GD, Warrier R, Nicely NI, Liao HX, Pollara J, et al. Human Non-Nutritionizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses During SHIV Macosal Infection in Rhesus Macaques. *Plos Pathog* (2015) 11(8):e1005042. doi: 10.1371/journal.ppat.1005042.

Anand SP, Prevost J, Baril S, Richard J, Medjahed H, Chapleau JP, et al. Two Families of Env Antibodies Efficiently Engage Fc-Gamma Receptors and Eliminate HIV-1-Infected Cells. *J Virol* (2019) 93(3):e01823–18. doi: 10.1128/JVI.01823-18.
139. Hua CK, Ackerman ME. Increasing the Clinical Potential and Applications of Anti-HIV Antibodies. Front Immunol (2017) 8:1665. doi: 10.3389/fimmu.2017.01655

140. Yang L, Wang P. Passive Immunization Against HIV/AIDS by Antibody Gene Transfer. Viruses (2014) 6(2):428–47. doi: 10.3390/v6020428

141. Keizer RJ, Huitema AD, Schellens JH, Beijnen JH. Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies. Clin Pharm (2010) 49(8):493–507. doi: 10.2165/11351280-000000000-00000

142. Balazs AB, Chen J, Hong CM, Rao DS, Yang L, Baltimore D. Antibody-Based Protection Against HIV Infection by Vectored Immunoprophylaxis. Nature (2011) 481(7379):81–4. doi: 10.1038/nature10660

143. Balazs AB, West AP Jr. Antibody Gene Transfer for HIV Immunoprophylaxis. Nat Immunol (2013) 14(1):1–5. doi: 10.1038/ni.2480

144. Johnson PR, Schnepf BG, Zhang J, Connell MJ, Greene SM, Yuste E, et al. Vector-Mediated Gene Transfer Engenders Long-Lived Neutralizing Activity and Protection Against SIV Infection in Monkeys. Nat Med (2009) 15(8):901–6. doi: 10.1038/nm.1967

145. Martinez-Navio JM, Fuchs SP, Pantryr SN, Lauer WA, Duggan NN, Keefe BF, et al. Adeno-Associated Virus Delivery of Anti-HIV Monoclonal Antibodies Can Drive Long-Term Virologic Suppression. Immunity (2019) 50(3):567–575.e565. doi: 10.1016/j.immuni.2019.02.005

146. Priddy FH, Lewis DJM, Gelderblom HC, Hassanin H, Streifeld C, LaBranche C, et al. Adeno-Associated Virus Vectored Immunoprophylaxis to Prevent HIV in Healthy Adults: A Phase 1 Randomised Controlled Trial. Lancet HIV (2019) 6(4):e230–9. doi: 10.1016/S2352-3018(19)30107-9

147. Haynes BF, Fleming J, St Clair EW, Katinger H, Stiegler G, Kunert R, et al. Cardiolipin Polyspecific Autorreactivity in Two Broadly Neutralizing Antibodies. Science (2005) 308(5730):1906–8. doi: 10.1126/science.1111781

148. Yang G, Holl TM, Liu Y, Li Y, Lu X, Nicely NI, et al. Identification of Autoantigens Recognized by the 2F5 and 4E10 Broadly Neutralizing HIV-1 Antibodies. J Exp Med (2013) 210(2):241–56. doi: 10.1084/jem.20121977

149. Liu M, Yang G, Wiehe K, Nicely NI, Vandergrift NA, Rutens T, Buckler-White A, et al. A Single Injection of Crystallizable Fragment Domain-Modified Antibodies Elicits Durable Protection From SHIV Infection. Nat Med (2018) 24(5):610–6. doi: 10.1038/s41591-018-0001-2

150. Ko SY, Pegu A, Rudicell RS, Yang ZY, Joyce MG, Chen X, et al. Enhanced Neonatal Fc Receptor Function Improves Protection Against Primate SHIV Infection. Nature (2014) 514(7524):642–5. doi: 10.1038/nature13612

151. Saunders KO, Pegu A, Georgiev IS, Zeng M, Joyce MG, Yang ZY, et al. Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection Against Simian/Human Immunodeficiency Virus Infection. J Virol (2015) 89(1):784–98. doi: 10.1128/JVI.02378-14

152. Gautam R, Nishimura Y, Szwarek K, Grimm SK, Lynch R, Yang G, Kozink DM, et al. Anti-Drug Antibody Responses Impair Prophylaxis Mediated by AAV-Delivered HIV-1 Broadly Neutralizing Antibodies. Mol Ther (2019) 27(3):650–60. doi: 10.1016/j.ymthe.2019.01.004

153. Bonsignori M, Wiehe K, Grimm SK, Lynch R, Yang G, Kozink DM, et al. An Autoactive Antibody From an SLE/HIV-1 Individual Broadly Neutralizes HIV-1. J Clin Invest (2014) 124(4):1835–43. doi: 10.1172/JCI71341

154. Hladik F, Hope TJ. HIV Infection of the Genital Mucosa in Women. Curr HIV/AIDS Rep (2009) 6(1):20–8. doi: 10.1007/s11904-009-0004-1

155. McElrath MJ, Setting the Stage: Host Invasion by HIV. Nat Rev Immunol (2008) 8(6):447–57. doi: 10.1038/nri2302

156. Alvarez RA, Barria MI, Chen BK. Unique Features of HIV-1 Spread Through T Cell Virological Synapses. PLoS Pathog (2014) 10(12):e1004513. doi: 10.1371/journal.ppat.1004513

157. Hladik F, McElrath MJ. Setting the Stage: Host Invasion by HIV. Nat Rev Immunol (2008) 8(6):447–57. doi: 10.1038/nri2302

158. Jolly C, Kashefi K, Hollinshead MJ, Sattentau QJ. HIV-1 Cell to Cell Transfer Across an Env-Induced, Actin-Dependent Synapse. J Exp Med (2004) 199(2):283–93. doi: 10.1084/jem.20030648

159. Sagar M. HIV-1 Transmission Biology: Selection and Characteristics of Infecting Viruses. J Infect Dis (2010) 202:S289–96. doi: 10.1086/556565

160. Moldt B, Rakasz EG, Schultz N, Chan-Hui P-Y, Swiderek K, Weisgrau KL, et al. Highly Potent HIV-Specific Antibody Neutralization In Vitro Translates Into Effective Protection Against Mucosal SHIV Challenge In Vivo. Proc Natl Acad Sci USA (2012) 109(46):18921–5. doi: 10.1073/pnas.1214785109

161. Liu M, Yang ZY, Boyington JC, Wu L, Co Y-S, Schmidt SD, et al. Neutralizing Antibodies to HIV-1 Envelope Protect More Effectively In Vivo Than Those to the CD4 Receptor. Sci Trans Med (2014) 6(243):243ra88. doi: 10.1126/scitranslmed.3008992

162. Parsons MS, Lloyd SB, Lee WS, Kristensen AB, Amarasinghe T, Center RJ, et al. Partial Efficacy of a Broadly Neutralizing Antibody Against Cell-Associated SHIV Infection. Sci Trans Med (2017) 9(402):eaaf1483. doi: 10.1126/scitranslmed.aaf1483

163. Sigal A, Kim JT, Balazs AB, Deka E, Mayo A, Milo R, et al. Cell-To-Cell Spread of HIV Pervades Ongoing Replication Despite Antiretroviral Therapy. Nature (2011) 477(7362):95–100. doi: 10.1038/nature10347

164. Liu Y, Cao W, Sun M, Li T. Broadly Neutralizing Antibodies for HIV-1: Efficacies, Challenges and Opportunities. Emerging Microbes Infect (2020) 9(1):194–206. doi: 10.1002/emmicro.217307

165. Duncan CIA, Williams JP, Schiffrin T, Gaertner K, Ochsnerbauer C, Kappes J, et al. High-Multiplicity HIV-1 Infection and Neutralizing Antibody Evasion Mediated by the Macrophage-T Cell Virological Synapse. J Virol (2014) 88(4):2053–4. doi: 10.1128/JVI.01934-13

166. Malbe C, Porrot F, Rua R, Horwitz J, Klein F, Halper-Stromberg A, et al. Broadly Neutralizing Antibodies That Inhibit HIV-1 Cell to Cell Transmission. J Exp Med (2013) 210(13):2813–21. doi:10.1084/jem.20131244

167. Reh L, Magnus C, Schanz M, Weber J, Uhr T, Rues T, et al. Capacity of Broadly Neutralizing Antibodies to Inhibit HIV-1 Cell-Cell Transmission Is Strain- and Epitope-Dependent. PLoS Pathog (2015) 11(7):e1004966. doi: 10.1371/journal.ppat.1004966

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.